Zyvac Tcv-PFS Vaccine contains Purified Vi Polysaccharide Typhoid Vaccine (25mcg) as its active ingredient and is indicated for the prevention of typhoid fever caused by Salmonella Typhi. This vaccine is a purified Vi capsular polysaccharide antigen that stimulates the immune system to produce protective antibodies against typhoid infection. Administered intramuscularly, Zyvac Tcv-PFS is typically recommended for individuals at risk of typhoid fever, including travelers to endemic areas, residents of regions with high incidence, and populations with limited access to clean water and sanitation. The vaccine is supplied in a pre-filled syringe (PFS) format, ensuring ease of administration and minimizing the risk of dosing errors. Zyvac Tcv-PFS is contraindicated in individuals with a known hypersensitivity to any component of the vaccine. Common adverse reactions are generally mild and may include local injection site pain, redness, swelling, and transient fever or malaise. Immunization with Zyvac Tcv-PFS does not provide protection against other Salmonella serotypes or other causes of febrile illness. Booster doses may be recommended based on risk assessment and local epidemiological data. Proper storage and handling are essential to maintain vaccine efficacy. Zyvac Tcv-PFS contributes significantly to typhoid fever control efforts in endemic regions and among at-risk populations.